AML Annihilation? New Therapy Unleashes Immune Army, Delivering Staggering Remission Rates!

A groundbreaking triple-drug therapy, ICT01 in combination with Aza-Ven, achieves a 96% composite complete remission rate in newly diagnosed AML patients unfit for intensive chemotherapy.
Remarkably, 74% of these patients reached complete remission, with high response rates even in traditionally resistant adverse- or intermediate-risk mutation groups.
Preliminary data shows an 83% overall survival rate at 9 months for patients on the 10mg ICT01 dose, heralding a new era for AML treatment.

For too long, acute myeloid leukemia (AML) has cast a long shadow, especially for older or unfit patients facing limited, non-curative treatments and grim survival odds⁶. Standard therapies like azacitidine and venetoclax (Aza-Ven) offer a lifeline, but relapse remains a stark reality⁶. Previous attempts to harness immunotherapy against AML have largely fallen short, leaving an urgent void.

But now, a beacon of hope emerges from ImCheck Therapeutics. At the upcoming ASCO 2025 Annual Meeting, the company will unveil stunning updated data from its EVICTION study. The star: ICT01, a "first-in-class" antibody that doesn't just fight cancer – it masterfully awakens the body's own elite γ9δ2 T cell fighting force^{1, 2}. When combined with Aza-Ven, this novel triple combination is achieving unprecedented results.

Imagine: 96% of these vulnerable patients achieving composite complete remission. Within that, a full 74% achieved complete remission. Even patients with adverse-risk mutations, typically less responsive, saw high success rates. And the fight doesn't stop there – an impressive 83% preliminary 9-month overall survival rate for those on 10mg of ICT01 underscores the profound clinical potential⁶. ICT01 targets BTN3A, a protein overexpressed on many cancers, selectively activating these potent γ9δ2 T cells, which then migrate into tumors and unleash an immunological cascade against the malignancy.

These groundbreaking findings, to be detailed in an oral presentation on June 2nd in Chicago, suggest ICT01 could revolutionize the AML treatment landscape. ImCheck is already planning to advance towards a randomized study, potentially cementing this therapy as a vital new weapon against a devastating disease⁶. More details on the EVICTION study can be found at NCT04243499.

AML Annihilation? New Therapy Unleashes Immune Army, Delivering Staggering Remission Rates!

References

Stay Updated!